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Abstract
In 1939, British psychiatrist Lionel Penrose described an inverse relationship between mental health treatment
infrastructure and criminal incarcerations. This relationship, later termed the ‘Penrose Effect’, has proven remarkably
predictive of modern trends which have manifested as reciprocal components, referred to as ‘deinstitutionalization’
and ‘mass incarceration’. In this review, we consider how a third dynamic—the criminalization of addiction via the ‘War
on Drugs’, although unanticipated by Penrose, has likely amplified the Penrose Effect over the last 30 years, with
devastating social, economic, and healthcare consequences. We discuss how synergy been the Penrose Effect and the
War on Drugs has been mediated by, and reflects, a fundamental neurobiological connection between the brain
diseases of mental illness and addiction. This neuroscience of dual diagnosis, also not anticipated by Penrose, is still
not being adequately translated into improving clinical training, practice, or research, to treat patients across the
mental illness-addictions comorbidity spectrum. This failure in translation, and the ongoing fragmentation and
collapse of behavioral healthcare, has worsened the epidemic of untreated mental illness and addictions, while driving
unsustainable government investment into mass incarceration and high-cost medical care that profits too exclusively
on injuries and multi-organ diseases resulting from untreated addictions. Reversing the fragmentation and decline of
behavioral healthcare with decisive action to co-integrate mental health and addiction training, care, and research—
may be key to ending criminalization of mental illness and addiction, and refocusing the healthcare system on
keeping the population healthy at the lowest possible cost.
Introduction
Mental illness, addictions, and their comorbid variants
(termed ‘dual diagnoses’) are poorly addressed by the U.S.
healthcare system due to relatively low insurance reim-
bursement, declining treatment infrastructure, and
insufficient professional training—allowing these brain
diseases to produce an increasingly large burden of sec-
ondary medical, economic, and social consequences1–3.
For Americans under 50, suicide and overdoses involving
addictive drugs are now both ranked in the top four
leading proximal causes of death4,5. As root cause
pathologies that eventually generate many other second-
ary organ injuries, cardiovascular diseases, cancers and
infections, undertreated addictions collectively represent
the largest public health threat and cause of early death in
the U.S6–8.
Toward unraveling the origins and complexities of this
healthcare crisis, at the core of which persists an
increasingly deficient behavioral healthcare system, this
review explores the synergistic effects of three long-
standing, interactive phenomena1: the ‘Penrose Effect’2;
the ‘War on Drugs’3; and a failure in translation of the
Neuroscience of Dual Diagnosis (i.e. the science that
describes the biological connections between addictions
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and mental illness). Explaining these trends and their
interactive dynamics, requires a weaving together of his-
torical, sociological, and neuroscientific perspectives, that
may inform a strategy for re-building behavioral health-
care as a core rather than marginal domain of the
healthcare system. This rebuilding, involving a more
complete, mainstream integration of addiction and men-
tal health services, professional training and research, may
be crucial for decisively reducing the twin challenges of
mass incarceration and the modern behavioral healthcare
crisis.
The Penrose Effect
In 1939, Lionel Penrose published his seminal theory
that in industrialized nations, a decline of mental health
treatment infrastructure is linked with reciprocal increa-
ses in incarcerations9 (Fig. 1). His analysis included cross-
sectional data from 18 European countries, showing an
inverse relationship between national volumes of psy-
chiatric beds and numbers of prisoners and crime mea-
sures9. This theory, subsequently termed the “Penrose
Effect”10, “Penrose Hypothesis”11, or “Penrose Law”12, has
been increasingly referred to in modern studies examining
the unintended consequences of deinstitutionalization13.
Beginning in the late 1960s, large-scale deinstitutionaliza-
tion commenced with depopulating and closure of long-
term inpatient psychiatric hospitals with plans to expand
outpatient community mental health services14,15. The
movement was driven by several agendas: to cut costs, to
improve civil rights and social integration for patients, and
(in what has proven to be an over-optimistic appraisal of the
therapeutic power of pharmaceuticals) to take advantage of a
growing repertoire of psychiatric medications to promote
healing aside from psychotherapies and environmental set-
tings14–16.
Problems with long-term psychiatric institutions were
widely publicized following the Rosenhan Experiment,
which highlighted the powerlessness, dehumanization, and
isolation of patients17. Stanford psychologist David
Rosenhan and seven other “pseudopatients” feigned audi-
tory hallucinations to gain admissions into psychiatric
wards, with plans to stop reporting symptoms immediately
after entering. The pseudopatients were subsequently
administered numerous psychotropic medications and were
stuck for an average of 19 days in these institutions.
Rosenhan concluded that community-based health
approaches should be pursued due to the counter-
therapeutic environment of institutionalization17. How-
ever, there was little evidence at the time to suggest
community-based health services would be built to com-
pensate for declining inpatient psychiatric services, or that
they would be less expensive14,15,18. Unfortunately, dein-
stitutionalization was poorly organized and conducted
without adequate build-up of supportive housing, social
services, or outpatient-community mental health infra-
structure19,20. Thus, deinstitutionalization has not only
created unprecedented waves of homelessness, but it has,
consistent with the Penrose Effect, forced the criminal
justice system to assume the role of mental healthcare, as
untreated, unsheltered individuals were relabeled as “crim-
inals”21–24.
As deinstitutionalization has progressed, evidence for
the Penrose Effect has accumulated internationally
including Argentina, Bolivia, Brazil, Chile, Paraguay, and
Uruguay20, Norway25, Hungary26, Ireland27, Finland28,
England, Spain, Sweden, Germany, the Netherlands29,30,
Australia31, and the U.S.32–35. Mundt et al. provides a
notable demonstration of a direct association between
deinstitutionalization and increasing prison populations
in six of the most populous countries in South America
from 1991 to 2012.20 Even after controlling for variance in
macroeconomic changes across these countries, the
numbers of psychiatric hospital beds had greatly reduced
where and when prison populations increased20.
Although both cross-sectional and longitudinal data
have been replicated in support of the Penrose Effect,
controversy remains about what mechanisms are driving
it, and/or whether it is an artifact of other phenomena,
such as changes in income inequality, unemployment,
macro-economies, social welfare programs, and/or chan-
ges in national healthcare systems11,13,14,19,36. Never-
theless, the existence of multiple forces contributing to
the inverse relationship between mental health treatment
infrastructure and prison populations does not preclude
the existence of the Penrose Effect, nor its consequences;
it only suggests the Penrose Effect is a complex
phenomenon.
One dynamic that may underpin the Penrose Effect is
increased labeling and categorization of behaviors,
resulting from untreated and unsheltered mental illness,
as minor forms of criminal activity, which would lead to
greater incarceration rates for mentally ill people. The
average number of state psychiatric hospital beds (U.S.)
Fig. 1 The Penrose Effect describes the inverse relationship
between mental health treatment infrastructure and prison
populations. Dotted arrows indicate one pathway underlying the
Penrose Effect in which removal of mental health treatment resources
leads to the criminalization of untreated mental illness resulting in
increased numbers of individuals with mental illness in correctional
facilities.
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has dropped from 339 per 100,000 in 1955 to ~14 per
100,000 in 2010 leaving 3.2 million individuals with ser-
ious mental illness to reside in the community22,37,38.
Mental illness rates and severity in U.S. prisons rose
steeply during this time. In 1870, <1% of prisoners had a
serious mental illness, yet today, that number is around
20% by conservative estimates22,39. By 2012, there were
nearly 10 times the number of persons with a mental
illness in prisons than in psychiatric hospitals39. In nearly
every U.S. state, a correctional facility holds more inmates
with a mental illness than the largest state psychiatric
hospital39.
Although antisocial traits and diagnoses are present
within mentally ill populations, this form of mental illness
only represents a small fraction of patients, and does not
represent the diversity of many other serious mental
disorders for which incarceration has replaced access to
appropriate treatment services and professionals22,37.
Without easy access to expert psychiatric treatment and
supportive, supervised housing, individuals with mental
illness navigate a society that has placed the criminal
justice system in front of, or between them and treat-
ment40,41. Consequently, a substantial population of
mentally ill now reside in correctional facilities40.
Remarkably, this state of affairs is not new. Despite
advances in psychiatric neuroscience, and the destigma-
tizing effects this science was hoped to bring, the U.S.
seems to have regressed significantly to a more primitive
approach that was the norm before the U.S. Civil War, in
which punishment was the first line approach for many
patients. In the 1840s, Dorothea Dix and other advocates
began to challenge state legislatures regarding the inhu-
mane treatment of mentally ill people in prisons; this
activism later spearheaded the building of a national
mental healthcare infrastructure and hospital system that
aimed to put treatment in front of punishment42,43.
The War on Drugs
The policy of addressing compulsive drug use (i.e.
addiction) as a crime in the modern era is commonly
referred to as “the War on Drugs” (Fig. 2). The War on
Drugs massively increased drug enforcement spending,
the scope of federal drug task forces44,45, and drug-related
arrests46,47. Although Prohibition in the 1920s can be
viewed as a failed, alcohol-specific prequel to the War on
Drugs48,49, the modern War on non-alcohol intoxicants
was formally launched by President Nixon in the early
1970s44. Since this time, the U.S. government, through
bipartisan decisions, has expended more than $1 trillion
on the War on Drugs at roughly $51 billion annually,
which is about 50 times the annual research budget on
addiction supported by the National Institute on Drug
Abuse46. Subsequent “tough on crime” policies produced
substantial increases in state, local, and federal police
funding between 1992 and 200844,45. This growth in the
size and power of the criminal justice system, has been
accompanied by growing concerns about its militariza-
tion, suppression of civil rights, and conduct operating
outside of constitutional law45,50–52. For example, the civil
forfeiture of assets in drug-related cases has permitted law
enforcement agencies to seize around $7 billion in assets
between 1985 and 1999 without due process rights50,52.
The War on Drugs has been enacted as a criminal-legal
approach to addiction in sharp contrast to biomedical
approaches, fundraising, and destigmatizing efforts that have
also been labeled as “Wars” on other diseases. For example,
the “War on Cancer” was also declared in the 1970s under
the Nixon administration but as an entirely biomedical
approach to find cures53,54. Few would argue that the War
on Cancer has been “won”; however, significant strides in
our understanding of cancer biology have led to dozens of
innovations in early detection and cancer therapies53,54.
Conversely, the War on Drugs has not encouraged progress
in treatment delivery or development and has failed to
reduce drug supply, drug-related crime, or addiction disease
rates and death46,52,55–57. In fact, the War on Drugs has been
shown to promote barriers to treatment and to increase
drug-related violence globally46,47,55. Likewise, viewing
addiction as a criminal behavior has resulted in increased
stigmatization, facilitated discriminatory racial policies, and
is linked with increased overdoses and the transmission
rates of HIV, hepatitis, and tuberculosis46,47,56–58.
Another widely recognized consequence of the War on
Drugs is the increased incarceration rate46,47. The number
of arrests for drug possession between 1982 and 2007 rose
from ~500,000 to 1.5 million, with arrests for all other
offenses (excluding assaults) declining during the same
timeframe44,45. This incarceration rate has allowed the
U.S. to become the world’s leader in per capita incar-
cerations; although making up just 5% of the world’s
population, it contains 25% of the world’s entire prison
population44,45,59,60.
Fig. 2 The War on Drugs describes a variety of legal policies that
attempt to solve addiction via criminal-justice and punitive
actions rather than biomedical-treatment approaches. The War
on Drugs has been shown to be a key driver in penal system
expansion. The dotted arrows indicate a pathway by which the
criminalization of behavior related to untreated addiction has led to
increased prison populations resulting from drug-related offenses.
Grecco and Andrew Chambers Translational Psychiatry           (2019) 9:320 Page 3 of 11
Comparable to how labeling mental illness-related
behavior as a crime may drive the Penrose Effect, the
War on Drugs has perpetuated beliefs, held by the public,
including members and stakeholders of the healthcare
industry, that addiction is a moral and criminal problem,
and not a biomedical problem. Although the U.S. bio-
medical research system has accumulated overwhelming
scientific proof that addiction is a highly prevalent brain
disease and a leading root cause of premature illness,
injury and death, the healthcare system ironically remains
extremely ill-equipped to adequately diagnose and treat
it6–8,61,62. Beyond this incapacity, the lack of professional
awareness and training about addictive diseases among
physicians has allowed the U.S. healthcare system to
directly contribute to the single largest outbreak of serious
addiction (and related illness and death) in U.S. history—
through the iatrogenic opioid epidemic63. Although the
opioid epidemic may have finally increased awareness of
addiction as a treatable brain disease, the building of
widely accessible treatment services and physician
expertise needed to address the epidemic has proven
elusive64,65. The road to parity of quality care for mental
illness and addictions (that is on par with treatment of
medical disease of body organs) remains largely blocked
by profound shortages of behavioral health professionals
and infrastructure, as well as entrenched stigma and
financial incentives that benefit from keeping addiction
framed as a criminal-legal issue rather than a biomedical
problem40,61,66.
The addiction–mental illness connection: the
science of dual diagnosis
Addictions and mental illnesses are tightly inter-
connected diseases both within individual brains67–70
and on population levels71–74 (Fig. 3). The biological
causal connection is involuntary and general across many
types of addictions and mental illnesses. This causal
connection is also bidirectional: having either illness
category increases the risk of acquiring the other, and
having either also worsens the severity of the other67,75.
This bi-directionality of causality is sufficient to explain
both the dense epidemiological overlap between these
illnesses and the fact that dual diagnosis patients face
greater degrees of virtually all quantifiable illness con-
sequences compared to their single disease counterparts,
including poorer psychosocial functioning, additional
medical comorbidities and service utilization, increased
risk for homelessness, suicide, overdose, and premature
death in general40,76,77.
The involuntary causal nature of the mental
illness–addiction connection is born out in both animal
and human research. Animal models of mental illness
show abnormal short and long-term motor and motiva-
tional reactions to addictive drug exposures whether they
are self-administered or delivered by researchers78,79. In
humans, the risk of acquiring addiction, illness severity,
and resistance to treatment is not related to an indivi-
dual’s choice or reasons for initially trying a drug, or their
capacity to express a desire to quit using; rather, addiction
risk and illness burden is increased with greater mental
illness severity76,80,81.
An important clue about the mental illness–addiction
connection is that this relationship is not specific to any
one addictive drug type, or intoxicating profile. For
example, it is constructive to compare nicotine and
opioids, which have very different psychoactive properties,
but are nevertheless both highly addictive, and very deadly
as addictions. Half of all cigarettes smoked in the U.S. are
consumed by only about 15% of the population—those
with some form of mental illness82. Likewise, about half of
all prescribed opioids in the U.S. are used by a similar
fraction of the total population—those with mental ill-
ness83. Even prior to the modern opioid epidemic, large
population-sample studies spanning decades have con-
sistently replicated the observation that substance dis-
orders are elevated 2–8-fold above the general population
across all of the major mental illnesses including psy-
chotic disorders, bipolar disorder, major depression, dys-
thymia, and personality disorders72,74,82,84–86. And again,
this connection, within each of these diagnostic cate-
gories, is not drug specific. Rather it is general to addic-
tion risk that spans many drug types. Thus addictions
involving nicotine, opioids, alcohol, stimulants, and can-
nabinoids are all elevated across a wide range of different
forms of mental illness72,73,87–90. As a reflection of this
phenomena, multiple addictions also routinely occur
together with mental illnesses in both individuals and
across whole clinical populations91. These ‘high-order’
dual diagnosis illnesses have been replicated in animal
modeling, reflecting the way mental illness biologically
Fig. 3 The addiction–mental illness connection. Mental illness and
addiction are highly comorbid diseases that have been demonstrated
to be deeply interconnected through alterations in shared neural
circuity and neurobiology, genetic risks, and environmental-
developmental risk factors. The biological-causal relationship is also
bidirectional: having either mental illness or addiction involuntarily/
biologically increases the likelihood and severity of acquiring
the other.
Grecco and Andrew Chambers Translational Psychiatry           (2019) 9:320 Page 4 of 11
increases addiction risk simultaneously across different
addictive drugs even with differing intoxication profiles70.
Only recently has the biological connection between
mental illness and addiction been recognized or under-
stood as a bidirectional causal problem. While it has been
known for decades that alcohol and drug use can induce
psychiatric symptoms in otherwise healthy people, or
worsen mental illness, it has been less clear if and how the
opposite happens, that is, how mental illness itself alters
the progression of addiction disease. However, animal
modeling and human neuroimaging evidence accumu-
lating since the 1990s has made it clear that mental illness
and addiction are inextricably linked on anatomical and
pathophysiological levels. Abnormal neurocircuitry pre-
sent in mental illness, even before drug exposure, changes
thresholds for becoming addicted and increases the speed
of disease progression and illness severity67,76,79,92. This
reality, being quite general to many combinations of
addictions and mental illness, likely reflects a fundamental
design motif (and vulnerability) of the mammalian brain.
All of the major limbic neural networks, including the
prefrontal cortex, hippocampal formation and amygdala—
which are each implicated across the major forms of
mental illness—densely project via glutamatergic con-
nections into the key motivational center of the brain,
where addiction disease is primarily centered—the
nucleus accumbens (or ventral striatum)67,93. This design
allows all of the higher order neural networks of the brain
(that represent and adapt contextual memory, emotion,
social-attachment, and decision-making functions) to
converge in the nucleus accumbens, where they con-
tribute to the neural representations and computations
that generate motivation92. Such an architecture opti-
mizes the brain’s capacity to integrate past experiences
and current cognitive states to best prioritize, sequence,
select, and adapt motivated behavior for long-term suc-
cess and survival. But, when one or more of these dis-
tributed limbic input territories to the nucleus accumbens
are structurally and functionally impaired—as in mental
illness—the function of the nucleus accumbens itself is
altered. This causes the acute and long-term neuroplastic
effects of dopamine neurotransmission that is pathologi-
cally evoked by addictive drug use, to have a much more
profound, long lasting, and devastating effect on moti-
vated behavior68,79,94,95.
Beyond this core frontal-cortical/temporal-limbic/ven-
tral-striatal circuity, additional cortical and deep brain
regions are increasingly implicated as neuroanatomical
zones where addiction and mental illness pathologies are
directly tied into one another. For example, recent studies
have implicated the lateral septum96, the habenula97, and
the insula98 in functions that integrate cognitive, emo-
tional, motivational, and appetitive control systems. Thus
across a broad swath of primary cortical-striatal and
accessory limbic networks of the brain, mental illness, and
addiction vulnerability are wired into one another and are
mechanistically unified to such an extent that in many
cases it is biophysically impossible to have one without
increasing vulnerability to the other. Hence addiction
vulnerability is a biologically intrinsic symptom of mental
illness that pervades different types of psychiatric
diagnoses.
Consistent with this integrated neurocircuit under-
standing of dual diagnosis, we are now gaining more
insight into how both genetic and environmental/devel-
opmental risk elements contribute to this core neurocircuit
vulnerability that gives rise to both mental illness and
addictions69,99–102. For example, twin studies and large
genome-wide association studies have identified shared
genetic risks for alcohol addiction and a range of mental
illnesses that are frequently comorbid with addictions
including schizophrenia, attention-deficit hyperactive dis-
order, and major depression103,104. Similarly, childhood
neglect, abuse and trauma, which collectively represent the
major non-genetic (i.e. environmental) root cause of adult
psychopathology, are also robust risk factors for acquiring
addiction71,105–107. With this evidence, it is becoming clear
that adverse childhood experiences and genetic determi-
nants work in concert during pre-adult neurodevelopment,
within the same cortical-striatal-limbic brain systems, to
produce both mental illness and addiction vulnerability108.
The science of dual diagnosis: a failure in
translation
Although mental illness and addiction share common
etiological factors, have overlapping neuroanatomies and
neurodevelopmental trajectories, show bidirectional
causality and a tight epidemiological overlap (such that
dual diagnosis patients represent the majority of all
behavioral health patients) these patients are often refer-
red to as ‘system misfits’ because of a lack of access to
integrative treatment services40,109,110. The highly frag-
mented behavioral healthcare system has been built and
operates in contradiction to this science: Federally spon-
sored psychiatric research (e.g. NIDA and NIAAA vs.
NIMH), professional training, treatment teams and
infrastructures, cultures of care, and insurance reimbur-
sement remain largely divided by a line that separates the
addiction vs. mental health-treatment fields108,111. Only
18% of addiction treatment programs and 9% of mental
health-treatment programs are considered dual diagnosis
capable111, while many cultural and structural barriers to
mental health–addiction integration persist despite dec-
ades of effort to create a national system of integrated
dual diagnosis treatment109–112.
The failure to translate the science of dual diagnosis
into driving the integration of clinical training and treat-
ment delivery—so that mental illnesses, addictions, and
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their bidirectional causal dynamics can be diagnosed and
treated by one healthcare team as comprehensively and
efficiently as possible108,112 has had significant public
health and social consequences. The iatrogenic opioid
epidemic has revealed the consequences of low medical
professional awareness of addiction, and disregard for the
risk for addiction in persons with mental illness, con-
tributing to the over prescription of high dose/chronic
opioids specifically to people with mental illness and
addictive disorders113,114. This targeting of vulnerable
brains with opioid overprescribing, termed by Sullivan
et al. as “Adverse Selection”, has occurred alongside
declines in behavioral health expertise, workforce, and
treatment access and an intensification of the War on
Drugs115.
Dual diagnosis and acceleration of the penrose
effect by the war on drugs
As reviewed thus far, mental illness and addiction are
brain diseases that, via the Penrose Effect and the War on
Drugs, have been marginalized by the healthcare system,
but absorbed by the legal system as reflecting criminal
behavior21,22,58,61,66. At the same time, however, the
neuroscience of dual diagnosis has characterized mental
illness and addiction as bi-directionally causative and
tightly interlinked brain diseases68,79,99,106,108. A key
implication of this neuroscience is that the Penrose Effect
and the War on Drugs are not merely parallel social
processes, but are interlinked and mutually reinforcing.
With a decline of mental health-treatment infrastructure,
we expect more people incarcerated for behaviors
resulting from untreated mental illness. Simultaneously,
because these populations are also biologically, invo-
luntarily predisposed to acquiring addictions, then
increasing numbers of people with mental illness living
without access to good mental health services likely
increases the numbers of patients who are acquiring
addictions, and demonstrating behavioral consequences
of untreated addiction, that are also criminalized by the
War on Drugs. Then, as the Penrose Effect is accelerated
by the War on Drugs, there is an ever greater transfer of
resources, workforce development, public funds, and
infrastructure away from treating either illness class as
healthcare issues, and instead, toward enforcement, pro-
secution, conviction, and mass incarceration of untreated
patients. These trends would thus intertwine to create a
feed-forward amplification of untreated addictions and
mental illness to crisis proportions, even to the extent
where advances in the neuroscience of these disorders
remain largely untranslated by an increasingly deficient
and fragmented behavioral healthcare system (Fig. 4).
Recent studies suggest a synergy between the Penrose
Effect and the War on Drugs has occurred in the U.S. and
internationally, in which mentally ill people are not
merely transferring out of treatment beds and into
incarceration beds in 1:1 ratios. To the extent that men-
tally ill people, due to their addiction comorbidities, have
been intensively subject to harsh drug penalties and the
criminalization of addiction, we might expect a much
more disproportionate exchange between treatment and
penal capacities. Thus, in a multinational South American
study examining the Penrose Effect from 1990 to 2012, for
every one mental health treatment bed that disappeared,
five more individuals ended up in prison, where, like in
the U.S., very high prevalence rates of mental illness and
addiction disorders have been identified20.
A national U.S. survey showed that individuals with a
dual diagnosis were nearly 7.5 times more likely to be
arrested in the last 12 months, compared to healthy
individuals, with only 1.8 or 5.3 fold increases in arrests in
persons with only a mental illness or an addiction116. In a
Seattle study, substance use seems to directly mediate the
relationship between a recent reduction in psychiatric
beds and an increase in jail detention for those with
mental illness32. Accordingly, a lack of substance disorder
treatment throughout mental healthcare is an important
risk factor for incarceration of patients with dual diag-
nosis77. Among individuals with a mental illness, co-
occurring substance use increases behaviors that are
criminalized (purchasing, dealing) leading to arrests and
incarcerations to such an extent that having a dual diag-
nosis has become a normalized characteristic of prison
populations117,118.
These observations suggest that deinstitutionalization
and the War on Drugs may have intersected to accelerate
the Penrose Effect, though multiple dynamics, at the core
Fig. 4 Acceleration of the Penrose Effect by the War on Drugs.
Through the fundamental neurobiological and clinical connections
between addiction and mental illness, the criminalization of
individuals with addiction promoted by the War on Drugs leads to an
acceleration of the Penrose Effect. This ultimately hastens the decline
and fragmentation of behavioral healthcare, while producing
explosive growth of the U.S. penal system, even as neuroscience that
is advancing our understanding addictions and mental illnesses as
brain diseases, remains increasingly disconnected and unapplied to
behavioral health care.
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of which is a fundamental epidemiological and neuro-
biological linkage between mental illness and addiction.
While Penrose may have had keen insight into the inverse
relationship between psychiatric beds and prison popu-
lations 80 years ago, he was unaware both of the neuro-
biology of drug addiction and its biological link with
mental illness, which have only been described in the last
30 years. Thus, he could not have predicted the impact
the War on Drugs might later have, to not only accelerate
the incarceration of mentally ill people (via their comor-
bid association with addiction), but the degree to which
the resulting growth of the penal system might actually
interdict the development and deployment of science-
based treatments, and contribute adversely to the degra-
dation of the behavioral healthcare system itself60,119.
The war and drugs as harm amplification
Aside from the channeling of public funds (and public
regard) away from behavioral healthcare, into criminal
justice approaches for addressing behaviors resulting from
untreated mental illness and addictions60, there is evi-
dence that the War on Drugs may directly worsen mental
illness via a process that can be termed as ‘Harm
Amplification’ (Fig. 5). Many treatments in mainstream
medical care, particularly for conditions that are difficult
to cure quickly or directly, pursue ‘Harm-Reduction’
strategies, where the therapeutic intervention seeks to limit
the negative overall functional impact and/or spread of the
injury or disease to other body organs. A cast on a broken
arm, insulin for diabetes, and opioid maintenance treat-
ments for opioid addiction are all evidence-based and
highly effective Harm-Reduction interventions. Oppositely,
the core strategy of the War on Drugs, through punishing
drug use and closely related behavior, represents Harm
Amplification, where various primary and secondary
damages associated with having the disease are deliberately
compounded by the criminal justice system (e.g. via public
humiliation, financial penalties, and incarceration), in
hopes that this will motivate effort in the individual to
abandon their addiction.
Beyond the removal of mentally ill/addicted patients
from access to mental health and addiction care more
generally available at higher standards outside of jails and
prisons39,58,60,120–122, incarceration settings frequently
tend to rely on behavioral control interventions that
encompass isolation techniques60, which are well known
to exacerbate brain abnormalities and behaviors that are
present in mental illness and addiction79,123. Additionally,
mentally ill patients face greater psychological and phy-
sical victimization in prison and disproportionate rates of
solitary confinement, symptom worsening, and higher
rates of suicide in prison39,60,120,124,125.
Dual diagnosis patients may be particularly adversely
affected by incarceration in terms of long-term out-
comes126,127. While lack of adequate addiction treatment is
a major risk factor for re-arrest following release58,60 indi-
viduals with dual diagnosis post-incarceration have a higher
risk for significant injuries (including drug-related and self-
harm) compared to their single disease counter-
parts77,126,128. Finally, the long-term and ‘collateral con-
sequences’ of criminalization of mental illness and addiction
are significant. Life post-incarceration often includes pro-
blems with reestablishing family bonds, extended unem-
ployment, lack of housing and access to health insurance, all
of which are essential for patients (and a well-functioning
behavioral health system needed to serve them)129,130. In
the absence of a strong outpatient system and physician
workforce that can provide integrated/longitudinal mental
health and addiction care, a large portion of individuals with
mental illness and addiction are stuck in repeated cycles
between emergency rooms and correctional facilities with-
out adequate care39,58,60,77,120,124. In turn, these patients and
their brain diseases are viewed, even by the healthcare
system and the insurance industry, as recidivistic, unde-
serving of healthcare resources, and essentially criminal.
These trends have contributed to a healthcare system that
has been negligent of addiction as a disease that is patho-
physiologically connected with mental illness. The seeds of
the modern iatrogenic opioid epidemic were thus planted,
leading to unprecedented levels of opioid addiction, mor-
tality, and criminal-legal consequences for addictions,
especially in mentally ill people63,114,131.
Conclusion
Eighty years ago, Penrose warned that reducing mental
health treatment infrastructure would result in increased
Fig. 5 Harm amplification. The mass criminalization of addiction and
mental illness has created a large population of individuals with these
diseases in a massively overgrown penal system. This enlargement
represents a barrier to treatment access for mental illness and
addiction for both un-incarcerated and incarcerated patients alike,
through reinforcing stigma and financial diversion away from
treatment into criminalization. For imprisoned patients, the penal
system may exacerbate symptomology and harm treatment access in
either disease domain via isolation/confinement practices,
victimization by other prisoners, disrupting family attachments,
hampering reentry into the community, and impairing access to
health insurance, employment and housing from months and years
after incarceration.
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prison populations. Dr. Penrose died just prior to the
advent of the War on Drugs which has likely functioned
as an unexpected accelerant of the Penrose Effect in the
modern era. Underpinning this acceleration, there exits
fundamental neurobiological, and epidemiological con-
nections between addictions and mental illness, as char-
acterized by a broad base of scientific evidence that is still
not being adequately translated to inform integrated
behavioral healthcare training, service delivery, and
treatment research. The associated decline and fragmen-
tation of behavioral healthcare, occurring despite major
advances in our neuroscientific understanding of addic-
tions and mental illness as brain diseases, is not only a
public health calamity, but jeopardizes the future of psy-
chiatric neuroscience itself, as this science continues to
show that it cannot be effectively translated to clinical
care, or, if there is no longer a functional behavioral health
system to translate to.
While having focused on the Penrose Effect as being
accelerated by the War on Drugs, it is also likely that the
reverse is simultaneously true: The War on Drugs and
associated consequences are probably also amplified by
the Penrose Effect. Increased incarceration of those with
untreated addiction would be exacerbated by a lack of
treatment resources for mental illness, and the even
greater paucity of integrated treatment services of addic-
tions in mentally ill people. In this way, a bidirectional
amplification of the Penrose Effect and the War on Drugs,
happening on the sociological-population scale parallels
the bidirectional causal connection and amplification that
exists between mental illness and addictions within the
brains of millions of individuals. The synergistic crim-
inalization of addiction and mental illness, coupled with a
failure in translating the neuroscience of dual diagnosis to
building a strong national system of integrated dual
diagnosis care, represents a critical failure of the U.S.
healthcare system. Large scale signs of this failure con-
tinue to emerge both in terms of the iatrogenic opioid
epidemic, and the recent decline in the life expectancy for
all Americans, which is the first such decline in the era of
modern medicine. This decline is remarkable not only for
being unique among advanced nations, but also for
principally reflecting increased mortality due to untreated
addictions and mental illness132–135.
From this big picture perspective, we can also infer that
mass incarceration and the modern healthcare crisis may
also be interlinked and even mutually reinforcing, as
mediated by the Penrose-War on Drugs Effect. Given the
depth and scope of expensive-to-treat injuries and chronic
medical diseases of the body that the U.S. healthcare
system is incentivized to treat (that frequently result from
untreated addictions), the American people pay for a
healthcare system that performs about as well as Cuba’s,
but at 14 times the cost136. Yet, ultimate responsibility for
solving this health crisis, must fall on the healthcare sys-
tem itself and not the criminal justice system, which is
equipped with professionals trained to carry out justice,
enforce laws, and punish crime, not to provide
healthcare21,23.
This big picture perspective may provide guidance for a
new national strategy needed to restore the cost-
effectiveness of U.S. healthcare and to decisively end
mass-incarceration. Reversing the Penrose Effect, ending
the War on Drugs (as a criminal-legal strategy), and
treating addictions and mental illness before they trans-
form into extremely expensive, lethal injuries, multi-organ
diseases, and/or prosecutable behavior, will require a non-
superficial rebuilding of the behavioral health workforce
and infrastructure. The neuroscience of dual diagnosis
should be expanded and advanced as a major (rather than
largely excluded) NIH research domain as contributed to
from across the NIAAA, NIDA, and NIMH portfolios.
This would better align their research missions with
addressing mental illness-addictions comorbidity as the
mainstream public health crisis that it actually represents,
allowing greater progress in the development of new
integrative and more parsimoniously effective pre-
ventative and treatment measures for dual diagnosis
conditions. Moreover, the science of dual diagnosis
available to us already, which so clearly highlights the
fallacy of segregating mental health from addiction
expertise and services, needs to be practically and fully
translated into a new system of clinics (and closely linked
inpatient units) that fully integrate the diagnosis and
treatment of mental illnesses and addictions, as provided
by cross-trained physicians, nurses, and therapists108,112.
This should occur along with removing the responsibility
placed on the criminal justice system for paying for, dic-
tating standards of care for, and providing addiction and
mental health treatment. If occurring in parallel with
efforts to achieve full parity of insurance coverage for
behavioral health on par with medical care, in a way that
completely separates insurance coverage and standards of
care from criminal-legal history, or incarceration status,
the U.S. might truly arrive at having the most advanced
and cost effective healthcare system in the world.
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